Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic melanoma.
Epistemonikos ID: 99b0ed82806020cd0d57379c2d10f24ff3fcf2b2
First added on: May 04, 2024